SCHEMBL3586377

SCHEMBL3586377

Cc1nc(C(F)(F)F)ccc1-c1nc(-c2cc(O)c(O)c([N+](=O)[O-])c2)co1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.37
CXCR4 P61073 1/20 0.37
COMT P21964 2/20 0.37
TTR P02766 3/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
PAX8 Q06710 1/20 0.35
MAOA P21397 3/20 0.35
MAPT P10636 2/20 0.34
PDE4B Q07343 1/20 0.34
MAOB P27338 2/20 0.34
GPR35 Q9HC97 4/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
ABCC3 O15438 1/20 0.34
ABCC4 O15439 1/20 0.34
NR1I2 O75469 1/20 0.34
ABCB11 O95342 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3588612 0.84 KDM4E (0.48) KDM4ECXCR4COMTTTRMEN1
SCHEMBL3586303 0.83 COMT (0.48) KDM4ECXCR4COMTTTRNPC1
SCHEMBL1447363 0.83 COMT (0.42) KDM4ECOMTTTRMEN1KMT2A
SCHEMBL3589121 0.82 COMT (0.41) KDM4ECXCR4COMTTTRMEN1
SCHEMBL3587929 0.82 TTR (0.38) KDM4ECOMTTTRMEN1KMT2A
SCHEMBL3588938 0.81 MAPT (0.37) KDM4ECOMTTTRMEN1KMT2A
SCHEMBL3582679 0.81 COMT (0.52) COMTTTRNPC1RAB9AMAPT
SCHEMBL3576471 0.81 EIF4E (0.46) EIF4E
SCHEMBL3587064 0.81 TTR (0.39) KDM4ECOMTTTRMEN1KMT2A
SCHEMBL3588972 0.80 TTR (0.39) KDM4ECXCR4COMTTTRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9446012-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-09-20 US disclosed
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2014-01-23 US disclosed
US-8536203-B2 Pharmaceutical compounds BIAL-PORTELA & CA, S.A. (PT) 2013-09-17 US disclosed
EP-2617713-A1 New Pharmaceutical Compounds BIAL - Portela & Ca., S.A. (PT) 2013-07-24 EP disclosed
US-20100168113-A1 Pharmaceutical Compounds BIAL-PORTELA & CA., S.A. (PT) 2010-07-01 US disclosed
EP-2027091-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - Portela & Ca., S.A. (PT) 2009-02-25 EP disclosed
CN-101248064-A Nitrocatechol derivatives as COMT inhibitors PORTELA & CA SA (PT) 2008-08-20 CN disclosed
WO-2007117165-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168113-A1 Pharmaceutical Compounds PMP22, CNR2, OPRL1 KDM4E 3648/4885CXCR4 894/4885COMT 10/4885
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS PMP22, CNR2, OPRL1 KDM4E 3648/4885CXCR4 894/4885COMT 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.